Clinical Trial Update: ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM) [Phase 3]

View source ↗

Summary

Phase 3 trial update for ADCTA as adjuvant immunotherapy in recurrent glioblastoma multiforme undergoing standard treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• ADCTA

Snippet

Sponsor: Safe Save Medical Cell Sciences & Technology Co.,Ltd. | Conditions: Glioblastoma Multiforme | Phase 3 | Status: UNKNOWN